# Weekly Briefing: Oct 19, 2026 **TL;DR:** Oral Wegovy + Foundayo now the two US oral options, Foundayo on track for EU approval, Fractyl's Revita shows promise for keeping weight off after stopping GLP-1s, muscle research pushes protein to 1.6-2.3g/kg fat-free mass plus lifting, and safety watch stays on NAION eye signal and compounded products. ## 💪 Motivational mindset to be strong and positive ### Resilience & inner strength This week's practice is returning, not forcing. Plant your feet, 3 slow breaths, then ask: "What is one kind, strong thing I can do in the next 10 minutes?" Small returns build self-trust more than perfect plans. ### Positive habits Anchor to what you already do. Water right after coffee. Protein first on your plate. Stand and stretch after messages. 2-line gratitude note before bed. After 60, consistency beats intensity every time. ### Overcoming self-doubt When the "I'm behind" story pops up, name it: "There's that doubt story." Then answer with a fact — a meal you made, a walk you took, a boundary you held. Facts steady you faster than arguing with fear. ## 🧘 Clarity practices ### Focus & decision-making Write the decision as one sentence. Pick just 2 criteria that matter this week — health + peace, for example. If an option fails both, park it for later. ### Mindfulness practices 60-second reset before meals: inhale 4, exhale 6, notice 3 things you see, 2 you hear, 1 you feel. It quiets noisy appetite cues and spinning thoughts. ### Organizing thoughts & priorities 3-minute brain dump on paper, then circle 3 that would make this week feel satisfying if done. Put those 3 on a sticky note; move the rest to "later" so your brain can let go. ### Calm & stress relief Close the day with: What went well? What's unfinished to carry kindly into next week? What's one small, kind thing for myself tonight? Let your body exhale before you plan more. ## 💊 GLP1 News ### New research & approvals As of October 2026, two oral options are approved in the US for weight management: Wegovy pill (semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 1, 2026).